Jan 09, 2013 | www.pharmaafrica.com
The Economic Times reports that Ahmedabad, India-based Amanta Biosciences, a manufacturer and marketer of sterile dosages said it has received approval from the South African Medicines Control Council for six products manufactured at the company’s Small Volume Parenterals (SVP) facility at Kheda in Gujarat.
The South African market estimated to be worth around $3.8 billion (2011), is growing at the rate of six per cent and is expected to reach $7 billion by 2018, with generics accounting for 60 per cent of the volume.
“The MCC approval will provide further impetus to our current expansion efforts in the African region. We would also augment our efforts by our own filing and licensing with new partners in South Africa. I see strong revenue potential in these underserved markets,” Amanta Biosciences’ Managing Director Bhavesh Patel said in an official statement.
The company is also looking to build on the MCC approval to export to other markets including Namibia, Botswana, Zimbabwe, Swaziland, Lesotho, Zambia, Malawi and Madagascar, all members of the Southern African Development Community (SADC), a regional body with a total of 15 member countries, including South Africa.
SADC has recently completed its own project proposal for initiating the process of medicines registration harmonization (MRH) in the region, and is expected to begin implementation of its own MRH project soon.
The East African Community (EAC), a regional intergovernmental organisation of five member countries including Kenya, Uganda, Tanzania, Rwanda and Burundi was the first to launch its MRH project in March last year. The process is is expected to reduce the time taken to register essential medicines for the treatment of priority diseases in the region.